FORTRESS BIOTECH, INC.

Consensus Fortress Biotech, Inc.

Stocks

FBIO

US34960Q3074

Pharmaceuticals

Market Closed - Nasdaq 16:00:00 2026-10-27 EDT			5-day change	1st Jan Change
1.930 ^USD	+3.21%		-0.52%	-47.27%

10-01	Fortress Biotech, Inc. Repays Remaining $15 Million Outstanding Principal Under Oaktree Agreement	CI
08-13	Fortress Biotech, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI

Evolution of the Average Target: Fortress Biotech, Inc.

Evolution of the Average Target - Fortress Biotech, Inc.

Evolution of the Target Price: Fortress Biotech, Inc.

Evolution of the Target Price - Fortress Biotech, Inc.

Changes in Analyst Recommendations: Fortress Biotech, Inc.

1b7d652ab914dd43f7aad640d23.-jVTwWxWlxXzZ5NQwNmgRZgOptMKMWq8AHmOLe9Sa1A.vmo7mSIRpEOSJPEfpq3CM9NB46NMW1rTVA3kWb1lMzygA2WWJhjvX4MB0g~0a36a2d0858af68552d83299d1cc4a61

Analysts' recommendations: Fortress Biotech, Inc.

25-10-01	Fortress Biotech and Cyprium Therapeutics Announce an Update on the NDA for CUTX-101	CI
25-10-01	Fortress Biotech Shares Drop After FDA Letter for CUTX-101 Manufacturing Facility	DJ
25-10-01	Fortress Biotech and Cyprium Therapeutics announce an update on the NDA for CUTX-101	RE
24-03-19	Alliance Global Partners Initiates Fortress Biotech at Buy Rating With $5 Price Target	MT
23-11-29	Roth MKM Lowers Price Target on Fortress Biotech to $15 From $30, Maintains Buy Rating	MT
23-08-22	B. Riley Trims Fortress Biotech's Price Target to $4 From $6, Keeps Buy Rating	MT
23-05-16	Cantor Fitzgerald Lowers Price Target on Fortress Biotech to $5 From $6, Maintains Overweight Rating	MT
22-08-04	Ladenburg Thalmann Starts Fortress Biotech at Buy With $6 Price Target	MT
22-07-14	B. Riley Securities Lowers Fortress Biotech's Price Target to $6 from $8, Keeps Buy Rating	MT
22-03-29	Benchmark Capital Adjusts Fortress Biotech's Price Target to $5 from $8, Keeps Buy Rating	MT
21-06-17	Fortress Biotech : B. Riley Lowers Fortress Biotech's PT to $8 from $9, Says Incremental Pipeline Updates Suggest Heightened Focus on Next-Gen Therapies; Keeps Buy Rating	MT
21-04-20	Fortress Biotech : Roth Capital Adjusts Price Target on Fortress Biotech to $5 From $4.50, Maintains Buy Rating	MT
21-04-05	Fortress Biotech : B. Riley Raises Fortress Biotech's Price Target to $9 from $8 After 'Strong' Q4 2020 Results, Keeps Buy Rating	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	FORTRESS BIOTECH, INC.			-	-	+167.38%
	ELI LILLY AND COMPANY					+4.27%
	JOHNSON & JOHNSON					+4.92%
	ABBVIE INC.					-0.68%
	ROCHE HOLDING AG					-2.56%
	MERCK & CO., INC.					+13.62%
	NOVARTIS AG					-2.85%
	ASTRAZENECA PLC					+22.47%
	AMGEN INC.					-10.64%
	GILEAD SCIENCES, INC.					+0.95%
	Average					+19.69%
	Weighted average by Cap.					+3.54%

See all sector performances

Analysts' Consensus

Sell

Consensus

Buy

Mean consensus

BUY

Number of Analysts

1

Last Close Price

1.930USD

Average target price

5.000USD

Spread / Average Target

+159.07%

High Price Target

5.000USD

Spread / Highest target

+159.07%

Low Price Target

5.000USD

Spread / Lowest Target

+159.07%

Analyst Consensus Detail

Analyst consensus - Fortress Biotech, Inc.

Consensus revision (last 18 months)

Consensus revision (last 18 months) - Fortress Biotech, Inc.

Stock Market
Stocks
FBIO Stock
Consensus Fortress Biotech, Inc.

The best tools reserved for subscribers to boost the performance of your investments!